YOLFTbeta
Zealand Pharma A/S

Zealand Pharma A/S

ZEAL · CO · Healthcare / Biotechnology

242.00DKK+0.90 (+0.37%)

Price History

Full chart

Market Stats

Previous Close241.10
Open238.00
Day Range237.50 – 246.80
52-Week Range233.50 – 556.00
Volume397.66K
Market Cap16.66B
P/E (TTM)6.50
Forward P/E11.16
EPS38.64
Dividend Yield0.00%
Beta0.61
50-Day Avg299.91
200-Day Avg327.37

About

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon for treating congenital hyperinsulinism. In addition, the company developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Adam Sinding Steensberg M.D.
  • Employees578
  • HeadquartersSydmarken 11, Søborg, Denmark, 2860, Denmark
  • Websitehttps://www.zealandpharma.com

Leadership

  • Mr. Adam Sinding Steensberg M.D.President & CEO · b. 1974
  • Ms. Henriette WennickeEVP & CFO · b. 1983
  • Mr. Ivan Mourits MollerExecutive VP & COO
  • Mr. Utpal SinghExecutive VP & Chief Scientific Officer · b. 1974
  • Mr. Eric RojasVP & Head of Investor Relations
  • Mr. Ravinder Singh ChahilEVP & General Counsel · b. 1968
  • Ms. Christina Sonnenborg BredalExecutive VP & Chief People Officer · b. 1985
  • Dr. Jens Damsgaard Mikkelsen M.D.Head of Molecular Pharmacology
  • Dr. David M. Kendall M.D.Executive VP, Chief Medical Officer & Head of R&D · b. 1961
  • Mr. Eric CoxExecutive VP & Chief Commercial Officer · b. 1967

Financials

Income Statement

Currency: DKK2007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue59.92M56.26M25.32M87.36M142.28M223.56M6.57M153.77M187.68M234.78M139.78M37.98M41.33M353.31M292.57M103.99M342.79M62.69M9.21B
Growth (%)--6.11%-55.00%+245.03%+62.88%+57.13%-97.06%+2239.11%+22.05%+25.10%-40.47%-72.83%+8.84%+754.80%-17.19%-64.46%+229.65%-81.71%+14598.86%
Cost of Revenue----112.00K15.93M872.00K13.78M22.27M31.46M14.63M180.24M415.00K90.56M118.81M30.71M19.17M7.87M28.19M
Gross Profit59.92M56.26M25.32M87.36M142.17M207.63M5.70M140.00M165.41M203.32M125.15M-142.26M40.92M262.75M173.75M73.28M323.61M54.82M9.19B
Gross Margin100.00%100.00%100.00%100.00%99.92%92.87%86.74%91.04%88.14%86.60%89.53%-374.60%99.00%74.37%59.39%70.47%94.41%87.44%99.69%
Operating Expense122.45M100.95M105.24M196.05M126.84M175.24M191.32M213.53M246.74M318.96M371.53M-794.65M628.86M1.09B1.22B889.87M895.85M1.33B2.03B
Operating Income-62.53M-44.69M-79.92M-108.70M15.33M32.40M-185.62M-73.54M-81.33M-115.65M-246.38M652.39M-587.94M-828.76M-1.05B-816.60M-572.24M-1.27B7.16B
Operating Margin-104.35%-79.43%-315.67%-124.43%10.77%14.49%-2823.52%-47.82%-43.33%-49.26%-176.27%1717.86%-1422.45%-234.57%-358.96%-785.30%-166.94%-2029.33%77.66%
EBITDA-62.53M-30.20M-72.56M-101.30M17.51M41.69M-177.76M-64.54M-75.11M-113.22M-250.39M-442.00M-559.74M-583.54M-729.68M-884.88M-651.58M-1.02B7.18B
EBITDA Margin-104.35%-53.68%-286.59%-115.96%12.30%18.65%-2704.06%-41.97%-40.02%-48.22%-179.14%-1163.87%-1354.23%-165.16%-249.41%-850.96%-190.08%-1621.76%77.95%
Net Income-55.00M-33.73M-80.03M-104.63M6.81M36.37M-183.76M-64.99M-113.96M-153.91M-272.27M581.28M-571.54M-846.73M-1.02B-965.61M-703.74M-1.08B6.46B
Net Income Margin-91.79%-59.96%-316.08%-119.78%4.79%16.27%-2795.21%-42.26%-60.72%-65.56%-194.79%1530.62%-1382.77%-239.65%-348.01%-928.60%-205.30%-1720.87%70.05%
R&D105.14M85.76M93.09M151.28M126.94M182.76M164.47M180.04M214.96M268.16M324.67M438.21M561.42M604.08M588.45M614.04M684.90M919.87M1.58B
R&D as % of Total Revenue175.47%152.44%367.68%173.17%89.21%81.75%2501.78%117.08%114.54%114.22%232.28%1153.90%1358.29%170.98%201.13%590.51%199.80%1467.30%17.19%
Interest Expense7.53M10.96M104.00K63.00K1.95M186.00K81.00K2.02M42.39M40.78M25.61M35.05M3.39M7.72M4.09M56.45M28.98M40.90M37.70M
Interest Expense % of Total Revenue12.56%19.47%0.41%0.07%1.37%0.08%1.23%1.31%22.59%17.37%18.32%92.30%8.20%2.19%1.40%54.29%8.45%65.24%0.41%

Balance Sheet

Currency: DKK2007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets263.37M225.24M158.68M450.55M469.48M522.40M346.91M596.76M634.69M694.63M737.24M1.23B1.60B1.92B2.07B1.54B1.98B9.51B16.46B
Total Liabilities21.00M16.61M25.75M43.44M28.08M31.39M30.77M343.93M382.46M416.43M208.77M113.52M356.84M747.52M1.14B723.89M387.15M888.86M1.63B
Total Equity242.37M208.63M132.92M407.11M441.40M491.01M316.14M252.83M252.23M278.19M528.47M1.12B1.24B1.18B927.80M815.91M1.59B8.62B14.83B
Cash246.30M209.68M144.62M383.31M278.34M358.85M286.18M538.27M418.80M323.33M588.72M860.63M1.08B860.77M1.13B1.07B449.31M480.30M4.58B
Total Debt6.12M------272.17M312.95M332.24M135.73M-85.76M119.85M787.43M443.47M119.23M391.76M405.77M
Net Debt-240.18M-209.68M-144.62M-383.31M-278.34M-358.92M-286.18M-266.10M-105.84M8.91M-452.98M-860.63M-995.30M-740.92M-341.67M-625.76M-330.08M-88.55M-4.17B

Cash Flow

Currency: DKK2007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-57.57M-28.62M-61.45M-55.98M-1.81M68.54M-169.62M-42.18M-225.41M40.90M-278.75M-460.40M-409.45M-688.72M-1.21B-942.21M-425.67M-930.82M6.53B
Investing Cash Flow-2.93M-3.47M-3.61M-54.13M-111.21M13.45M96.81M19.76M-4.01M-299.96M221.35M881.90M-51.67M-196.81M-18.12M281.26M-1.09B-7.33B-2.25B
Financing Cash Flow-4.71M-6.30M-348.80M8.06M--272.17M96.41M157.15M337.93M-155.45M674.48M760.94M1.33B587.40M907.01M8.29B-378.18M
Capital Expenditure2.38M3.37M3.57M4.24M11.47M8.85M4.57M4.50M4.04M2.60M7.23M4.04M23.52M25.04M22.13M11.71M23.75M13.15M33.37M
Free Cash Flow-59.95M-31.99M-65.03M-60.22M-13.28M59.69M-174.19M-46.68M-229.45M38.30M-285.97M-464.44M-432.97M-713.76M-1.23B-953.92M-449.42M-943.96M6.50B
Dividends Paid--------------647.91M----
FCF to OCF104.13%111.78%105.82%107.57%735.38%87.09%102.69%110.66%101.79%93.64%102.59%100.88%105.74%103.64%101.83%101.24%105.58%101.41%99.49%
Dividend Paid to FCF---------------52.50%----

Earnings

Report DateJun 1, 2011Aug 18, 2011Nov 17, 2011Mar 15, 2012Apr 25, 2012Aug 23, 2012Nov 13, 2012Mar 14, 2013May 15, 2013Aug 29, 2013Nov 15, 2013Mar 20, 2014Apr 29, 2014Aug 21, 2014Nov 7, 2014Mar 13, 2015May 22, 2015Aug 28, 2015Nov 5, 2015Mar 16, 2016May 18, 2016Aug 25, 2016Nov 9, 2016Mar 15, 2017May 17, 2017Aug 24, 2017Nov 8, 2017Mar 7, 2018May 16, 2018Aug 16, 2018Nov 15, 2018Mar 7, 2019May 16, 2019Aug 15, 2019Nov 14, 2019Mar 12, 2020May 14, 2020Aug 13, 2020Nov 12, 2020Mar 11, 2021May 12, 2021Aug 12, 2021Nov 11, 2021Mar 10, 2022May 12, 2022Aug 11, 2022Nov 10, 2022Mar 2, 2023May 11, 2023Aug 17, 2023Nov 9, 2023Feb 27, 2024May 16, 2024Aug 15, 2024Nov 7, 2024Feb 20, 2025May 8, 2025Aug 14, 2025Nov 12, 2025Feb 19, 2026May 6, 2026Aug 12, 2026Nov 12, 2026
EPS Estimate-1.30-1.20-3.201.500.49-2.20--1.61-2.10-1.61--2.00-0.40-2.70-1.98-2.30-2.364.21-3.13-3.52-2.481.50-0.90-2.91-2.23-3.76-2.71-3.27-3.40-5.40-1.52-2.05-2.17-1.05-4.87-0.20-4.99-7.74-6.17-6.84-7.00-6.35-6.70-10.20-5.20-5.75-3.90-4.69-2.33-3.85-4.20-3.98-3.47-4.29-0.64109.53-10.42-8.17-9.1621.34-9.94
EPS Actual-1.964.11-0.64-0.842.883.93-0.02-2.28-2.52-2.08-1.53-1.971.27-2.100.74-2.64-2.45-3.39-2.233.17-3.05-4.10-1.292.11-1.03-3.66-1.48-3.64-2.98-4.18-3.64-4.01-4.13-4.33-3.44-5.01-4.98-1.57-5.76-9.68-5.78-6.87-4.61-6.49-2.43-11.04-3.29-6.61-3.76-5.501.23-4.60-3.71-4.67-3.77-4.12-4.75105.61-5.75-5.19-5.5855.34-
Surprise-216.15%46.67%--10.00%162.00%-104.08%-3.64%--29.19%27.14%-22.36%--5.00%285.00%2.22%-23.74%-47.39%5.51%-24.70%2.56%-16.48%47.98%40.67%-14.44%-25.77%33.63%3.19%-9.96%-27.83%-7.06%25.74%-171.71%-111.22%-58.53%-377.14%-2.26%-685.00%-15.43%-25.06%6.32%-0.44%34.14%-2.20%63.73%-8.24%36.73%-14.96%3.59%-17.27%152.79%-19.48%11.67%-17.34%-8.65%3.96%-642.19%-3.58%44.82%36.47%39.08%159.33%-
Timing-After-hoursAfter-hours-Pre-marketAfter-hours-Pre-market--Pre-marketPre-market-Pre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-market-Pre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursPre-market

Key Statistics & Ratios

Market Cap16.66B
Enterprise Value4.44B
Trailing P/E6.50
Forward P/E11.16
PEG Ratio0.31
Price / Sales3.59
Price / Book1.05
EPS38.64
Book Value259.59
Revenue (TTM)4.64B
Gross Profit (TTM)4.64B
EBITDA2.32B
Profit Margin59.02%
Operating Margin85.93%
Return on Equity16.31%
Return on Assets7.81%
Shares Outstanding66.33M
Shares Float59.41M
Beta0.61
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%